Shield Therapeutics (STX) H1 2024 earnings summary

Executive summary

• H1 2024 revenues reached $12.1 million, a 3.5x increase year-over-year, driven by strong US ACCRUFeR® sales, higher net price per prescription, and global partnerships.

• ACCRUFeR® prescriptions in the US grew 161% year-over-year to 65,200, with Viatris co-commercialization expanding reach and driving growth.

• Peak revenue potential for ACCRUFeR® is estimated at $450 million, with current US market share at 3%.

• Global partnerships in Europe, Canada, Korea, and China are progressing, with milestone and royalty payments expected.

• Focus remains on US market growth, with international expansion managed through partners to minimize resource stretch.

Financial highlights

• US ACCRUFeR® net revenues reached $11 million in H1 2024, up 3.5x year-over-year; ex-US revenue was $1.1 million, up from $0.6 million.

• Total revenues were $12.1 million, with gross profit rising to $5.5 million from $1.7 million year-over-year.

• Operating loss widened to $15.5 million, mainly due to increased SG&A expenses from US salesforce expansion.

• Cash and cash equivalents at H1 2024 end were $8.1 million, with an additional $5.7 million received post-period from milestone monetization.

• Net cash outflow from operations improved to $3.6 million, aided by working capital inflow.

Outlook and guidance

• Break-even and cash flow positivity are expected in H2 2025 based on current growth trajectory.

• Net realized price per prescription is targeted to rise to $200–$220 over the next 8–18 months.

• Pediatric study completion in 2024 is expected to expand future market opportunities in the US and EU.

• ACCRUFeR® approval in China is expected by YE 2026; Korea approval anticipated in 2025.

• Minimum revenue targets are set for upcoming quarters as part of financing covenants.